---
title: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
date: '2023-11-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37952132/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231112170743&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: Among patients with subclinical atrial fibrillation, apixaban
  resulted in a lower risk of stroke or systemic embolism than aspirin but a higher
  risk of major bleeding. (Funded by the Canadian Institutes of Health Research and
  others; ARTESIA ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. (Funded by the Canadian Institutes of Health Research and others; ARTESIA ClinicalTrials.gov number, ...